Beijing SL Pharmaceutical Co., Ltd. 002038.SZ Stock
Beijing SL Pharmaceutical Co., Ltd. Price Chart
Beijing SL Pharmaceutical Co., Ltd. 002038.SZ Financial and Trading Overview
| Beijing SL Pharmaceutical Co., Ltd. stock price | 8.39 CNY |
| Previous Close | 9.77 CNY |
| Open | 9.74 CNY |
| Bid | 9.77 CNY x 0 |
| Ask | 9.78 CNY x 0 |
| Day's Range | 9.69 - 9.89 CNY |
| 52 Week Range | 7.78 - 10.4 CNY |
| Volume | 14.94M CNY |
| Avg. Volume | 13.51M CNY |
| Market Cap | 10.04B CNY |
| Beta (5Y Monthly) | 0.46541 |
| PE Ratio (TTM) | 25.710527 |
| EPS (TTM) | 0.31 CNY |
| Forward Dividend & Yield | 0.1 (1.02%) |
| Ex-Dividend Date | June 29, 2022 |
| 1y Target Est | N/A |
002038.SZ Valuation Measures
| Enterprise Value | 9.12B CNY |
| Trailing P/E | 25.710527 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 9.361403 |
| Price/Book (mrq) | 1.7702483 |
| Enterprise Value/Revenue | 8.509 |
| Enterprise Value/EBITDA | 31.797 |
Trading Information
Beijing SL Pharmaceutical Co., Ltd. Stock Price History
| Beta (5Y Monthly) | 0.46541 |
| 52-Week Change | 1.24% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 10.4 CNY |
| 52 Week Low | 7.78 CNY |
| 50-Day Moving Average | 9.34 CNY |
| 200-Day Moving Average | 8.88 CNY |
002038.SZ Share Statistics
| Avg. Volume (3 month) | 13.51M CNY |
| Avg. Daily Volume (10-Days) | 25.56M CNY |
| Shares Outstanding | 1.03B |
| Float | 621.9M |
| Short Ratio | N/A |
| % Held by Insiders | 41.37% |
| % Held by Institutions | 2.56% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.1 |
| Trailing Annual Dividend Yield | 1.02% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.2703 |
| Last Split Factor | 1.5:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 34.79% |
| Operating Margin (ttm) | 15.85% |
| Gross Margin | 85.99% |
| EBITDA Margin | 26.76% |
Management Effectiveness
| Return on Assets (ttm) | 1.78% |
| Return on Equity (ttm) | 6.64% |
Income Statement
| Revenue (ttm) | 1.07B CNY |
| Revenue Per Share (ttm) | 1.06 CNY |
| Quarterly Revenue Growth (yoy) | 8.00% |
| Gross Profit (ttm) | N/A |
| EBITDA | 286.93M CNY |
| Net Income Avi to Common (ttm) | 373.04M CNY |
| Diluted EPS (ttm) | 0.38 |
| Quarterly Earnings Growth (yoy) | 219.00% |
Balance Sheet
| Total Cash (mrq) | 844.16M CNY |
| Total Cash Per Share (mrq) | 0.82 CNY |
| Total Debt (mrq) | 0 CNY |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 7.29 |
| Book Value Per Share (mrq) | 5.519 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 420.4M CNY |
| Levered Free Cash Flow (ttm) | 103.66M CNY |
Profile of Beijing SL Pharmaceutical Co., Ltd.
| Country | China |
| State | N/A |
| City | Beijing |
| Address | Building 1, Bitongyuan |
| ZIP | 100049 |
| Phone | 86 10 8862 7635 |
| Website | https://www.slpharm.com.cn |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 757 |
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; ciclosporin; mycophenolate mofetil dispersible; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin (salmon); paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is based in Beijing, the People's Republic of China.
Q&A For Beijing SL Pharmaceutical Co., Ltd. Stock
What is a current 002038.SZ stock price?
Beijing SL Pharmaceutical Co., Ltd. 002038.SZ stock price today per share is 8.39 CNY.
How to purchase Beijing SL Pharmaceutical Co., Ltd. stock?
You can buy 002038.SZ shares on the Shenzhen exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Beijing SL Pharmaceutical Co., Ltd.?
The stock symbol or ticker of Beijing SL Pharmaceutical Co., Ltd. is 002038.SZ.
Which industry does the Beijing SL Pharmaceutical Co., Ltd. company belong to?
The Beijing SL Pharmaceutical Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Beijing SL Pharmaceutical Co., Ltd. have in circulation?
The max supply of Beijing SL Pharmaceutical Co., Ltd. shares is 1.03B.
What is Beijing SL Pharmaceutical Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Beijing SL Pharmaceutical Co., Ltd. PE Ratio is 27.06451800 now.
What was Beijing SL Pharmaceutical Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Beijing SL Pharmaceutical Co., Ltd. EPS is 0.31 CNY over the trailing 12 months.
Which sector does the Beijing SL Pharmaceutical Co., Ltd. company belong to?
The Beijing SL Pharmaceutical Co., Ltd. sector is Healthcare.